Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells

Hepato-Gastroenterology

Volumn 60, Issue 125, 2013, Pages 1199-1205

  Kanemaru, Mikio ^a   Maehara, Naoki ^a   Chijiiwa, Kazuo ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

1 ,25 dihydroxyvitamin D3; p21; Pancreatic cancer; Proliferation; VDR

Indexed keywords

CALCITRIOL; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MESSENGER RNA; PROTEIN P27; VITAMIN D RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CALCITRIOL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, CALCITRIOL; UP-REGULATION;

EID: 84885784070     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge11073     Document Type: Article

References (38)

1. Li D, Xie K, Wolff R, Abbruzzese JL: Pancreatic cancer. Lancet 2004;363:1049-1057. (Pubitemid 38410779)
2. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001; 60:8-18.
3. Rocha Lima CM, Urbanic JJ, Lal A: Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Semin Oncol 2001; 28:34-43. (Pubitemid 32757658)
4. Ward S, Morris E, Bansback N, et al.: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer. Health Technol Assess 2001; 5:1-70.
5. Stathopoulos GP, Mavroudis D, Tsavaris N, et al.: Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12:101-103. (Pubitemid 32162454)
6. Crane CH, Wolff RA, Abbruzzese JL, et al.: Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 2001; 28:25-33. (Pubitemid 32757657)
7. van Moorsel CJ, Veerman G, Bergman AM, et al.: Combination chemotherapy studies with gemcitabine. Semin Oncol 1997; 24;S7-17.
8. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF: Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206:1188-1190. (Pubitemid 10159658)
9. Abe E, Miyaura C, Sakagami H, et al.: Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981; 78:4990-4994. (Pubitemid 12225607)
10. Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80:1678S-1688S.
11. Colston K, Hirt M, Feldman D: Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology 1980; 107:1916-1922. (Pubitemid 11194706)
12. Chen TC, Holick MF: Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 2003; 14:423-430. (Pubitemid 37392215)
13. Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132:1952-1960. (Pubitemid 23133240)
14. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J: Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 1997; 42:31-41. (Pubitemid 27056726)
15. Inoue T, Kamiyama J, Sakai T: Sp1 and NF-Y synergistically mediate the effect of vitamin D(3) in the p27(Kip1) gene promoter that lacks vitamin D response elements. J Biol Chem 1999; 274:32309-32317.
16. Hager G, Formanek M, Gedlicka C, et al.: 1,25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 2001; 121:103-109. (Pubitemid 32205033)
17. Wu G, Fan RS, Li W, Ko TC, Brattain MG: Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997; 15:1555-1563. (Pubitemid 27464648)
18. Kawa S, Yoshizawa K, Nikaido T, Kiyosawa K: Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. J Steroid Biochem Mol Biol 2005; 97:173-177. (Pubitemid 41546227)
19. Colston KW, James SY, Oforl-Kuragu EA, Binderup L, Grant AG: Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br J Cancer 1997; 76:1017-1020. (Pubitemid 27434657)
20. Iwamura T, Katsuki T, Ide K: Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987; 78:54-62. (Pubitemid 17037867)
21. Iwamura T, Katsuki T: Kinetics of carcinoembryonic antigen and carbohydrate antigen 19-9 production in a human pancreatic cancer cell line (SUIT-2). Gastroenterol Jpn 1987; 22:640-646. (Pubitemid 17161876)
22. Taniguchi S, Iwamura T, Katsuki T: Correlation between spontaneous metastatic potential and type I collagenolytic activity in a human pancreatic cancer cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992; 10:259-266.
23. Iwamura T, Taniguchi S, Kitamura N, et al.: Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2). J Gastroenterol Hepatol 1992; 7:512-519.
24. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP: Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 1997; 19:15-27. (Pubitemid 27345239)
25. Verlinden L, Verstuyf A, Convents R, et al.: Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 1998; 142:57-65. (Pubitemid 28438279)
26. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000; 408:307-310.
27. Skinner HG, Michaud DS, Giovannucci E, et al.: Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev 2006; 15:1688-1695. (Pubitemid 44497105)
28. Mizoue T: Ecological study of solar radiation and cancer mortality in Japan. Health Phys 2004; 87:532-538
29. Boscoe FP, Schymura MJ: Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006; 6:264.
30. Grant WB: An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer 2007; 120:1123-1128.
31. Hansen CM, Frandsen TL, Brünner N, Binderup L: 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994; 12:195-202.
32. Martell RE, Strahler JR, Simpson RU: Identification of lamin B and histones as 1,25-dihydroxyvitamin D3-regulated nuclear phosphoproteins in HL-60 cells. J Biol Chem 1992; 267:7511-7519.
33. Hansen CM, Madsen MW, Arensbak B, et al.: Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes Commun 1998; 5:109-120.
34. Gedlicka C, Hager G, Weissenbock M, et al.: 1,25(OH)2Vitamin D3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 2006; 35:472-478. (Pubitemid 44212901)
35. Wang QM, Luo X, Studzinski GP: Cyclin-dependent kinase 6 is the principal target of p27/Kip1 regulation of the G1-phase traverse in 1,25-dihydroxyvitamin D3-treated HL60 cells. Cancer Res 1997; 57:2851-2855. (Pubitemid 27315026)
36. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP: Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996; 10:142-153. (Pubitemid 26049905)
37. Munker R, Zhang W, Eistner E, Koeffler HP: Vitamin D analogs, leukemia and WAF1. Leuk Lymphoma 1998; 31:279-284. (Pubitemid 29033948)
38. Kawa S, Nikaido T, Aoki Y, et al.: Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br J Cancer 1997; 76:884-889. (Pubitemid 27401939)